Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $886M | $904M | $968M | $988M | $870M | $993M | $1.17B | $1.31B | $1.36B | $1.33B |
| Revenue growth | — | 2.0% | 7.0% | 2.2% | -11.9% | 14.1% | 17.7% | 12.0% | 4.0% | -2.0% |
| Gross profit | $378M | $412M | $418M | $485M | $398M | $506M | $615M | $692M | $749M | $788M |
| Gross margin | 42.7% | 45.6% | 43.2% | 49.0% | 45.7% | 50.9% | 52.6% | 52.8% | 55.0% | 59.0% |
| Operating income | -$19.4M | $56.2M | $83.5M | $103M | $89.7M | $80.8M | $156M | $165M | $222M | $157M |
| Operating margin | -2.2% | 6.2% | 8.6% | 10.5% | 10.3% | 8.1% | 13.4% | 12.6% | 16.3% | 11.7% |
| Net income | -$26.3M | $45.6M | $55.0M | $76.5M | $79.5M | $43.4M | $115M | $118M | $168M | $97.3M |
| Net margin | -3.0% | 5.0% | 5.7% | 7.7% | 9.1% | 4.4% | 9.9% | 9.0% | 12.3% | 7.3% |
| EPS (diluted) | -$0.51 | $0.85 | $1.04 | $1.48 | $1.55 | $0.84 | $2.24 | $2.29 | $3.31 | $2.05 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $160M | $220M | $159M | $158M | $109M | $172M | $273M | $182M | $182M | $293M |
| Capital expenditures | $76.1M | $74.8M | $119M | $48.8M | $37.0M | $96.5M | $191M | $38.1M | $39.3M | $32.8M |
| Free cash flow | $83.6M | $146M | $40.3M | $109M | $71.8M | $75.8M | $81.7M | $144M | $142M | $260M |
| Share buybacks | $0.00 | $100M | $160M | $175M | $0.00 | $0.00 | $75.0M | $0.00 | $225M | $175M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $140M | $180M | $169M | $137M | $192M | $259M | $284M | $179M | $307M | $245M |
| Total assets | $1.24B | $1.24B | $1.27B | $1.27B | $1.82B | $1.86B | $1.93B | $2.20B | $2.45B | $2.40B |
| Long-term debt | $254M | $59.4M | $322M | $306M | $691M | $559M | $754M | $798M | $921M | $1.22B |
| Shareholders' equity | $740M | $752M | $668M | $587M | $732M | $749M | $818M | $960M | $821M | $796M |
| Retained earnings | $290M | $267M | $161M | $78.5M | $158M | $202M | $253M | $360M | $352M | $279M |
| Shares (wtd avg diluted) | 51.5M | 53.5M | 52.9M | 51.8M | 51.3M | 51.4M | 51.4M | 51.4M | 50.7M | 47.4M |
Every figure is extracted from HAEMONETICS CORP’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.